Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

ConclusionsDasatinib can be safely combined with trastuzumab and paclitaxel. The combination is active with an ORR of almost 80%.Trial registration: NCT01306942, EudraCT 2010-023304-27.

Source: Breast Cancer Research and Treatment - January 3, 2019 Category: Cancer & Oncology Source Type: research